Skip to main content

Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity

International Urogynecology Journal volume 19, Article number: 1353 (2008) Cite this article

Abstract

The objective of the study was to evaluate the local effects of three antimuscarinics excreted into human urine after oral ingestion. Two normal adult collected their voided urine after taking oral doses of tolterodine, darifenacin, and solifenacin for 7 days with a 14-day washout period. The urodynamic effect of intravesically administered human urine on carbachol-induced bladder overactivity was studied in female rats. Cystometric parameters were measured during continuous infusion of saline and human urine and then a mixture of carbachol (30 µM) and human urine. Carbachol significantly reduced the intercontraction interval and bladder capacity in the control (urine taken in the absence of oral antimuscarinics) and tolterodine- or darifenacin-administered groups. However, human urine obtained after taking solifenacin prevented the carbachol-induced detrusor overactivity. Urine excreted after oral ingestion of solifenacin provides a localized pharmacological advantage for the treatment of the overactive bladder syndrome.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Abrams P, Cardozo L, Fall M, Grififiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standarisation of terminology of lower urinary tract function: report from the Standarisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178

    PubMed  Article  Google Scholar 

  2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff JW, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766

    PubMed  Article  CAS  Google Scholar 

  3. Chapple C, Khullar V, Gabriel Z, Dooley JA (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48:5–26

    PubMed  Article  CAS  Google Scholar 

  4. Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor—which is the main mechanism of action? Eur Urol 43:1–5

    PubMed  Article  CAS  Google Scholar 

  5. de Groat WC (2004) The urothelium in overactive bladder: passive bystander or active participant? Urology 64(6 Suppl 1):7–11

    PubMed  Google Scholar 

  6. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R (2000) Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 129:416–419

    PubMed  Article  CAS  Google Scholar 

  7. Yoshida M, Inadome A, Murakami S, Otani M, Miyamae K, Iwashita H et al (2003) Effects of age and bladder stretching on non-neurogenic acetylcholine release from human bladder. J Urol 169:316

    Article  Google Scholar 

  8. Michel MC, Hegde SS (2006) Treatment of the overactive bladder syndrome with muscarinic receptor antagonists—a matter of metabolites? Arch Pharmacol 374:79–85

    Article  CAS  Google Scholar 

  9. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Intl 97:400–403

    Article  CAS  Google Scholar 

  10. Guay DRP (2003) Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 42:1243–1285

    PubMed  Article  CAS  Google Scholar 

  11. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E (2005) Muscarinic receptors subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144:1089–1099

    PubMed  Article  CAS  Google Scholar 

  12. Chai TC, Sun Y (2006) Augmented extracellular ATP signaling in bladder urothelium cells from patients with interstitial cystitis. Am J Physiol Cell Physiol 290:C27–34

    PubMed  Google Scholar 

  13. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65:238–242

    PubMed  Article  Google Scholar 

  14. Iijima K, De Wachter S, Wyndaele JJ (2007) Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 52:842–847

    PubMed  Article  Google Scholar 

  15. Finney SM, Andersson KE, Gillespie JI, Stewart LH (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98:503–507

    PubMed  Article  CAS  Google Scholar 

  16. Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987–1006

    PubMed  CAS  Google Scholar 

  17. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J (2005) for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470

    PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

Grant support from Astellas US Pharma.

Author information

Affiliations

  1. Department of Urology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, 123, Ta-Pei Road, Niao-Song Hsiang, Kaohsiung Hsien, Taiwan

    Yao-Chi Chuang

  2. Center for Urologic Research Excellence Institute, Pittsburgh, PA, USA

    Catherine A. Thomas & Shachi Tyagi

  3. Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Naoki Yoshimura & Pradeep Tyagi

  4. Department of Urology, William Beaumont Hospital, Royal Oak, MI, USA

    Michael B. Chancellor

Authors
  1. Yao-Chi Chuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine A. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shachi Tyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoki Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pradeep Tyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael B. Chancellor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yao-Chi Chuang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chuang, YC., Thomas, C.A., Tyagi, S. et al. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int Urogynecol J 19, 1353 (2008). https://doi.org/10.1007/s00192-008-0650-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00192-008-0650-7

Keywords

  • Detrusor overactivity
  • Antimuscarinics
  • Solifenacin
  • Darifenacin
  • Tolterodine